Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study Meeting Abstract
| Authors: | Cunningham, D.; Tebbutt, N. C.; Davidenko, I.; Murad, A. M.; Al-Batran, S. E.; Ilson, D. H.; Tjulandin, S.; Gotovkin, E.; Karaszewska, B.; Bondarenko, I.; Tejani, M. A.; Udrea, A. A.; Tehfe, M. A.; Baker, N.; Oliner, K. S.; Zhang, Y. L.; Hoang, T.; Sidhu, R.; Catenacci, D. V. T. |
| Abstract Title: | Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900839 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.4000 |
| Notes: | Meeting Abstract: 4000 -- Source: Wos |
